Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CNAT

Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis

Conatus Pharmaceuticals logo

About Conatus Pharmaceuticals Stock (NASDAQ:CNAT)

Advanced Chart

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.56
$1.34
52-Week Range
$0.23
$1.07
Volume
570 shs
Average Volume
1.28 million shs
Market Capitalization
$928,760.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNAT Stock News Headlines

See More Headlines

CNAT Stock Analysis - Frequently Asked Questions

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS) and Dextera Surgical (DXTR).

Company Calendar

Last Earnings
5/01/2020
Today
1/23/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNAT
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-11,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.72 million
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$928,760.00
Optionable
Not Optionable
Beta
1.84
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CNAT) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners